Transplant recipients are vulnerable to coverage denial under Medicare Part D

Transplant immunosuppressants are often used off‐label because of insufficient randomized prospective trial data to achieve organ‐specific US Food and Drug Administration (FDA) approval. Transplant recipients who rely on Medicare Part D for immunosuppressant drug coverage are vulnerable to coverage...

Ausführliche Beschreibung